What is DFPH's health score?

Oncology Institute, Inc. (DFPH) has a TradeApes health score of 54 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is DFPH's estimated fair value?

Based on our 5-year discounted cash flow model, Oncology Institute, Inc.'s estimated fair value is $5.02 per share, representing a 7.0% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is DFPH undervalued or overvalued?

Our model currently rates DFPH as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for DFPH... Refresh in a moment for the full analysis.

Oncology Institute, Inc. (DFPH)

Healthcare Fair Value low mixed

Updated: 2026-06-06

TradeApes Score

Financial Strength

60 Healthy

Operating Trend

55 Mixed

Relative Value

50 Mixed

Capital Allocation

45 Mixed

Risk

55 Mixed

Est. Fair Value $5.02

DCF Upside +7.0%

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.